165 related articles for article (PubMed ID: 28155878)
21. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
22. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
23. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
Wennier ST; Brinkmann K; Steinhäußer C; Mayländer N; Mnich C; Wielert U; Dirmeier U; Hausmann J; Chaplin P; Steigerwald R
PLoS One; 2013; 8(8):e73511. PubMed ID: 23951355
[TBL] [Abstract][Full Text] [Related]
24. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
[TBL] [Abstract][Full Text] [Related]
25. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.
Clark RH; Kenyon JC; Bartlett NW; Tscharke DC; Smith GL
J Gen Virol; 2006 Jan; 87(Pt 1):29-38. PubMed ID: 16361415
[TBL] [Abstract][Full Text] [Related]
26. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Gorse GJ; Newman MJ; deCamp A; Hay CM; De Rosa SC; Noonan E; Livingston BD; Fuchs JD; Kalams SA; Cassis-Ghavami FL;
Clin Vaccine Immunol; 2012 May; 19(5):649-58. PubMed ID: 22398243
[TBL] [Abstract][Full Text] [Related]
27. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.
Sumner RP; Ren H; Ferguson BJ; Smith GL
Vaccine; 2016 Sep; 34(40):4827-34. PubMed ID: 27544585
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
Kim TW; Lee JH; He L; Boyd DA; Hung CF; Wu TC
Hum Gene Ther; 2005 Jan; 16(1):26-34. PubMed ID: 15703486
[TBL] [Abstract][Full Text] [Related]
29. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
30. CD4+ T cell help is dispensable for protective CD8+ T cell memory against mousepox virus following vaccinia virus immunization.
Fang M; Remakus S; Roscoe F; Ma X; Sigal LJ
J Virol; 2015 Jan; 89(1):776-83. PubMed ID: 25355885
[TBL] [Abstract][Full Text] [Related]
31. The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses.
Pérez P; Martín-Acebes MA; Poderoso T; Lázaro-Frías A; Saiz JC; Sorzano CÓS; Esteban M; García-Arriaza J
Emerg Microbes Infect; 2021 Dec; 10(1):1441-1456. PubMed ID: 34213405
[TBL] [Abstract][Full Text] [Related]
32. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
33. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
34. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.
Olson MR; Hartwig SM; Varga SM
J Immunol; 2008 Dec; 181(11):7958-68. PubMed ID: 19017987
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
Staib C; Kisling S; Erfle V; Sutter G
J Gen Virol; 2005 Jul; 86(Pt 7):1997-2006. PubMed ID: 15958679
[TBL] [Abstract][Full Text] [Related]
36. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
[TBL] [Abstract][Full Text] [Related]
37. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.
Schell TD
J Virol; 2004 Feb; 78(4):1751-62. PubMed ID: 14747540
[TBL] [Abstract][Full Text] [Related]
38. Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis.
Rattanasena P; Anraku I; Gardner J; Le TT; Wang XJ; Khromykh AA; Suhrbier A
Immunol Cell Biol; 2011 Mar; 89(3):426-36. PubMed ID: 20680025
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
40. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates.
Zhan Y; Deng Y; Huang B; Song Q; Wang W; Yang Y; Dai L; Wang W; Yan J; Gao GF; Tan W
Vaccine; 2019 Apr; 37(15):2122-2130. PubMed ID: 30851967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
